Market Cap | 168.61M | P/E | 32.82 | EPS this Y | -42.20% | Ern Qtrly Grth | - |
Income | 8.72M | Forward P/E | 18.05 | EPS next Y | -23.10% | 50D Avg Chg | 6.00% |
Sales | 219.14M | PEG | 0.04 | EPS past 5Y | - | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 6.52 | EPS next 5Y | 232.50% | 52W High Chg | -30.00% |
Recommedations | 3.00 | Quick Ratio | 1.20 | Shares Outstanding | 49.05M | 52W Low Chg | 74.00% |
Insider Own | 15.15% | ROA | 6.02% | Shares Float | 32.47M | Beta | 1.08 |
Inst Own | 69.80% | ROE | 22.10% | Shares Shorted/Prior | 3.62M/4M | Price | 3.61 |
Gross Margin | 73.08% | Profit Margin | 3.98% | Avg. Volume | 216,567 | Target Price | - |
Oper. Margin | -4.63% | Earnings Date | Oct 31 | Volume | 122,028 | Change | 1.69% |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
HC Wainwright & Co. | Buy | Aug 2, 24 |
HC Wainwright & Co. | Buy | Jul 26, 24 |
HC Wainwright & Co. | Buy | Jun 4, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | May 20, 24 |
HC Wainwright & Co. | Buy | May 3, 24 |
HC Wainwright & Co. | Buy | Mar 1, 24 |
HC Wainwright & Co. | Buy | Feb 13, 24 |
HC Wainwright & Co. | Buy | Sep 20, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Dec 04 | Sell | 3.7608 | 280 | 1,053 | 97,934 | 01/10/24 |
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Jan 03 | Sell | 4.4859 | 7,733 | 34,689 | 98,214 | 01/05/24 |
Ludwig Jeffrey Jerome | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Sell | 4.4859 | 12,956 | 58,119 | 99,970 | 01/05/24 |
AUERBACH ALAN H | President and CEO President and CEO | Jan 03 | Sell | 4.4859 | 41,396 | 185,698 | 6,936,947 | 01/05/24 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Jan 03 | Sell | 4.4859 | 15,682 | 70,348 | 128,666 | 01/05/24 |
HUNT DOUGLAS M | See Remarks See Remarks | Jan 03 | Sell | 4.4859 | 8,358 | 37,493 | 103,319 | 01/05/24 |
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Jul 03 | Sell | 3.3112 | 6,938 | 22,973 | 105,947 | 07/06/23 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Jul 03 | Sell | 3.3112 | 14,680 | 48,608 | 144,348 | 07/06/23 |
Ludwig Jeffrey Jerome | Chief Commercial Off.. Chief Commercial Officer | Jul 03 | Sell | 3.3112 | 12,103 | 40,075 | 112,926 | 07/06/23 |
HUNT DOUGLAS M | See Remarks See Remarks | Jul 03 | Sell | 3.3112 | 7,809 | 25,857 | 111,677 | 07/06/23 |
AUERBACH ALAN H | President and CEO President and CEO | Jul 03 | Sell | 3.3112 | 60,698 | 200,983 | 6,978,343 | 07/06/23 |
WILSON TROY EDWARD | Director Director | Jun 13 | Sell | 3.45 | 27,000 | 93,150 | 350 | 06/15/23 |
MOYES JAY M | Director Director | Jun 13 | Sell | 3.45 | 22,000 | 75,900 | 16,322 | 06/15/23 |
Stuglik Brian M | Director Director | Jun 13 | Sell | 3.46 | 9,900 | 34,254 | 31,958 | 06/15/23 |
Senderowicz Adrian | Director Director | Jun 13 | Sell | 3.45 | 27,000 | 93,150 | 06/15/23 | |
Dorval Allison | Director Director | Jun 13 | Sell | 3.45 | 10,000 | 34,500 | 17,000 | 06/15/23 |
MILLER MICHAEL PATRICK | Director Director | Jun 13 | Sell | 3.45 | 13,500 | 46,575 | 41,358 | 06/15/23 |
AUERBACH ALAN H | President and CEO President and CEO | Jan 03 | Sell | 4.1779 | 27,241 | 113,810 | 6,852,638 | 01/05/23 |
AUERBACH ALAN H | President and CEO President and CEO | Dec 02 | Sell | 4.49780 | 1,251 | 5,627 | 6,311,698 | 12/06/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Dec 02 | Sell | 4.49780 | 429 | 1,930 | 75,575 | 12/06/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Dec 02 | Sell | 4.49780 | 159 | 715 | 110,926 | 12/06/22 |
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Dec 02 | Sell | 4.49780 | 514 | 2,312 | 58,013 | 12/06/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Nov 02 | Sell | 2.25 | 429 | 965 | 76,004 | 11/04/22 |
AUERBACH ALAN H | President and CEO President and CEO | Nov 02 | Sell | 2.25 | 1,242 | 2,794 | 6,312,949 | 11/04/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Nov 02 | Sell | 2.25 | 163 | 367 | 111,085 | 11/04/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Oct 03 | Sell | 2.3354 | 165 | 385 | 111,248 | 10/05/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Oct 03 | Sell | 2.3354 | 435 | 1,016 | 76,433 | 10/05/22 |
AUERBACH ALAN H | President and CEO President and CEO | Oct 03 | Sell | 2.3354 | 1,260 | 2,943 | 6,314,191 | 10/05/22 |
MILLER MICHAEL PATRICK | Director Director | Aug 09 | Sell | 3.5517 | 25,000 | 88,792 | 54,858 | 08/10/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Aug 02 | Sell | 2.89 | 161 | 465 | 111,577 | 08/04/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Jul 05 | Sell | 2.6315 | 9,328 | 24,547 | 111,738 | 08/04/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Aug 02 | Sell | 2.89 | 429 | 1,240 | 77,301 | 08/04/22 |
AUERBACH ALAN H | President and CEO President and CEO | Aug 02 | Sell | 2.89 | 1,247 | 3,604 | 6,316,705 | 08/04/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Jul 05 | Sell | 2.6315 | 3,753 | 9,876 | 77,730 | 07/07/22 |
AUERBACH ALAN H | President and CEO President and CEO | Jul 05 | Sell | 2.6315 | 26,140 | 68,787 | 6,317,952 | 07/07/22 |
Ludwig Jeffrey Jerome | Chief Commercial Off.. Chief Commercial Officer | Jul 05 | Sell | 2.6315 | 5,835 | 15,355 | 64,625 | 07/07/22 |
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Jul 05 | Sell | 2.6315 | 2,920 | 7,684 | 58,527 | 07/07/22 |
Senderowicz Adrian | Director Director | Jun 16 | Sell | 2.6313 | 27,858 | 73,303 | 27,000 | 06/21/22 |
WILSON TROY EDWARD | Director Director | Jun 16 | Sell | 2.5835 | 27,858 | 71,971 | 27,350 | 06/21/22 |
Stuglik Brian M | Director Director | Jun 16 | Sell | 2.686 | 13,000 | 34,918 | 41,858 | 06/21/22 |
MOYES JAY M | Director Director | Jun 16 | Sell | 2.6411 | 22,858 | 60,370 | 38,322 | 06/21/22 |
Wong Alvin F | Chief Scientific Off.. Chief Scientific Officer | Jun 02 | Sell | 1.9241 | 587 | 1,129 | 61,447 | 06/06/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Jun 02 | Sell | 1.9218 | 162 | 311 | 121,066 | 06/06/22 |
HUNT DOUGLAS M | See Remarks See Remarks | Jun 02 | Sell | 1.9441 | 417 | 811 | 81,483 | 06/06/22 |
AUERBACH ALAN H | President and CEO President and CEO | Jun 02 | Sell | 1.9441 | 1,200 | 2,333 | 6,344,092 | 06/06/22 |
HUNT DOUGLAS M | See Remarks See Remarks | May 03 | Sell | 2.3101 | 438 | 1,012 | 81,900 | 05/05/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | May 03 | Sell | 2.3401 | 165 | 386 | 121,228 | 05/04/22 |
AUERBACH ALAN H | President and CEO President and CEO | May 03 | Sell | 2.3201 | 1,263 | 2,930 | 6,345,292 | 05/04/22 |
AUERBACH ALAN H | President and CEO President and CEO | Apr 04 | Sell | 3.078 | 1,198 | 3,687 | 6,346,555 | 04/05/22 |
NOUGUES MAXIMO F | Chief Financial Offi.. Chief Financial Officer | Apr 04 | Sell | 3.078 | 206 | 634 | 121,393 | 04/05/22 |